Brokerages expect MEI Pharma, Inc. (NASDAQ:MEIP) to report earnings per share (EPS) of ($0.07) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for MEI Pharma’s earnings. MEI Pharma reported earnings per share of ($0.15) in the same quarter last year, which indicates a positive year-over-year growth rate of 53.3%. The business is scheduled to report its next quarterly earnings results on Thursday, February 4th.
On average, analysts expect that MEI Pharma will report full-year earnings of ($0.51) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.42). For the next fiscal year, analysts expect that the company will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.79) to ($0.26). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for MEI Pharma.
MEI Pharma (NASDAQ:MEIP) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.18). MEI Pharma had a negative net margin of 142.81% and a negative return on equity of 33.55%. The company had revenue of $3.83 million during the quarter, compared to analyst estimates of $2.48 million.
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of Montreal Can bought a new position in shares of MEI Pharma in the 2nd quarter valued at approximately $28,000. Brooks Moore & Associates Inc. bought a new position in shares of MEI Pharma in the 3rd quarter valued at approximately $34,000. State of Wisconsin Investment Board bought a new position in shares of MEI Pharma in the 2nd quarter valued at approximately $44,000. HighMark Wealth Management LLC bought a new position in shares of MEI Pharma in the 3rd quarter valued at approximately $52,000. Finally, Private Advisor Group LLC bought a new position in shares of MEI Pharma in the 2nd quarter valued at approximately $53,000. 54.58% of the stock is owned by institutional investors.
Shares of NASDAQ MEIP opened at $2.64 on Wednesday. MEI Pharma has a one year low of $0.72 and a one year high of $4.46. The firm has a market capitalization of $297.06 million, a PE ratio of -4.40 and a beta of 1.71. The business has a 50-day moving average price of $2.87 and a two-hundred day moving average price of $3.04.
MEI Pharma Company Profile
MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.
Featured Story: What is the LIBOR?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.